Fred Alger Management LLC reduced its stake in shares of Merus (NASDAQ:MRUS - Free Report) by 18.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 47,288 shares of the biotechnology company's stock after selling 10,658 shares during the period. Fred Alger Management LLC owned 0.07% of Merus worth $1,988,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Deutsche Bank AG raised its stake in shares of Merus by 0.4% in the 4th quarter. Deutsche Bank AG now owns 113,056 shares of the biotechnology company's stock valued at $4,754,000 after acquiring an additional 416 shares in the last quarter. DAFNA Capital Management LLC grew its holdings in Merus by 9.5% during the fourth quarter. DAFNA Capital Management LLC now owns 451,804 shares of the biotechnology company's stock valued at $18,998,000 after purchasing an additional 39,231 shares during the last quarter. Baker BROS. Advisors LP raised its position in shares of Merus by 50.0% in the fourth quarter. Baker BROS. Advisors LP now owns 450,000 shares of the biotechnology company's stock valued at $18,922,000 after purchasing an additional 150,000 shares during the period. Algert Global LLC lifted its stake in shares of Merus by 12.6% in the fourth quarter. Algert Global LLC now owns 173,114 shares of the biotechnology company's stock worth $7,279,000 after buying an additional 19,390 shares during the last quarter. Finally, Alyeska Investment Group L.P. bought a new stake in shares of Merus during the 4th quarter worth $5,734,000. Institutional investors and hedge funds own 96.14% of the company's stock.
Merus Price Performance
Shares of MRUS traded down $1.49 on Tuesday, hitting $40.92. The company's stock had a trading volume of 598,476 shares, compared to its average volume of 718,211. The company has a market capitalization of $2.83 billion, a PE ratio of -10.36 and a beta of 0.94. Merus has a fifty-two week low of $33.19 and a fifty-two week high of $61.61. The company has a 50 day moving average price of $43.43 and a 200 day moving average price of $43.96.
Merus (NASDAQ:MRUS - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($1.40) EPS for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.23). Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. The business had revenue of $26.49 million during the quarter, compared to analyst estimates of $7.82 million. On average, equities analysts forecast that Merus will post -3.85 EPS for the current year.
Analysts Set New Price Targets
A number of research analysts have weighed in on MRUS shares. HC Wainwright reissued a "buy" rating and set a $85.00 target price on shares of Merus in a research report on Monday, March 3rd. Wells Fargo & Company cut their target price on Merus from $91.00 to $89.00 and set an "overweight" rating for the company in a research note on Thursday, May 8th. Piper Sandler started coverage on Merus in a research report on Thursday, February 13th. They issued an "overweight" rating and a $84.00 target price for the company. Needham & Company LLC reissued a "buy" rating and issued a $83.00 price target on shares of Merus in a report on Wednesday, April 9th. Finally, William Blair restated an "outperform" rating on shares of Merus in a research note on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $85.15.
Get Our Latest Report on MRUS
About Merus
(
Free Report)
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.
Featured Articles
Before you consider Merus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merus wasn't on the list.
While Merus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
